首页|期刊导航|北京大学学报（医学版）|柳氮磺吡啶在我国类风湿关节炎患者的用药现况调查

柳氮磺吡啶在我国类风湿关节炎患者的用药现况调查

刘田王彩虹王永福杨荣王国春卢昕朱平陈丽娜靳洪涛刘湘源孙琳王秀茹陈海英崔刘福舒荣刘白鹭张卓莉李光韬李振彬杨静李俊芳贾彬安媛张风肖陶杰梅韩淑玲林金盈韦美秋刘晓敏柯丹胡绍先叶丛杨岫岩周云杉李昊黄慈波高明赖蓓李兴福宋立军王轶王晓元穆荣苏茵张晓盈栗占国段天骄朱佳鑫李晓峰王莉枝

北京大学学报（医学版）2012，Vol.44Issue(2)：188-194,7.

北京大学学报（医学版）2012，Vol.44Issue(2)：188-194,7.DOI:10.3969/j.issn.1671-167X.2012.02.006

柳氮磺吡啶在我国类风湿关节炎患者的用药现况调查

Sulphasalazine in patients with rheumatoid arthritis in China: a cross-sectional study

刘田 ¹王彩虹 ²王永福 ³杨荣 ⁴王国春 ⁴卢昕 ⁵朱平 ⁵陈丽娜 ⁶靳洪涛 ⁶刘湘源 ⁷孙琳 ⁸王秀茹 ⁸陈海英 ¹崔刘福 ²舒荣 ⁹刘白鹭 ¹⁰张卓莉 ¹⁰李光韬 ¹⁰李振彬 ¹¹杨静 ¹¹李俊芳 ¹²贾彬 ¹²安媛 ¹³张风肖 ¹³陶杰梅 ¹韩淑玲 ²林金盈 ¹⁴韦美秋 ¹⁴刘晓敏 ¹⁵柯丹 ¹⁶胡绍先 ¹⁶叶丛 ¹⁷杨岫岩 ¹⁷周云杉 ¹⁸李昊 ¹⁸黄慈波 ¹⁹高明 ¹赖蓓 ²李兴福 ¹⁹宋立军 ²⁰王轶 ²⁰王晓元 ²⁰穆荣 ²¹苏茵 ²¹张晓盈 ²²栗占国 ²²段天骄 ¹朱佳鑫 ¹李晓峰 ¹王莉枝²

作者信息

1. 北京大学人民医院风湿免疫科,北京100044
2. 北京大学首钢医院多顶街社区卫生中心全科
3. 山西医科大学第二医院风湿免疫科,太原030001
4. 包头医学院第一附属医院风湿免疫科,包头014010
5. 中日友好医院风湿免疫科,北京100029
6. 第四军医大学西京医院风湿免疫科,西安710032
7. 河北医科大学第二医院风湿免疫科,石家庄050000
8. 北京大学第三医院风湿免疫科,北京100191
9. 河北医科大学第三医院风湿免疫科,石家庄050051
10. 华北煤炭医学院附属开滦医院风湿免疫科,唐山063000
11. 北京大学第一医院风湿免疫科,北京100034
12. 白求恩国际和平医院风湿免疫科,石家庄050082
13. 河北邯郸中心医院风湿免疫科,邯郸056001
14. 河北省人民医院风湿免疫科,石家庄050051
15. 北京大学首钢医院风湿免疫科,北京100144
16. 广西壮族自治区人民医院风湿免疫科,南宁530021
17. 北京顺义区医院风湿免疫科,北京101300
18. 华中科技大学同济医学院附属同济医院风湿免疫科,武汉430030
19. 中山医科大学附属第一医院风湿免疫科,广州510080
20. 北京医院风湿免疫科,北京100730
21. 山东大学齐鲁医院风湿免疫科,济南250012
22. 兰州大学第二医院风湿免疫科,兰州730030
折叠

摘要

Abstract

Objective;To investigate the medication status of rheumatoid arthritis (RA) patients and to analyze the clinical use of sulphasalazine (SSZ) and the adverse effect. Methods; A total of 1 096 outpatients and inpatients diagnosed with RA were investigated in 21 hospitals all over China from July 2009 to December 2010, including gender, age of onset, clinical manifestations, as well as the clinical characteristics and medication status of 160 RA patients who received SSZ therapy. Results;In the group of 160 patients who received SSZ, the male-to-female ratio was 1: 7, The average age at onset was (46. 1 ?15.0) years, while the average course was (9.9 ?. 8) years. The average dose of sulphasalazine was ( 1. 87 ?. 52) g/d for a mean duration of (26. 3 ?14. 6) months. Only 17% (27/160) of the patients received SSZ monotherapy. Methotrexate (63. 1%), leflunomide (36.2%) and hydroxychloroquine (18. 1% ) were most commonly used combination drugs. And 36. 2% (58/160) of the patients used the two-drug combination of methotrexate plus sulphasalazine . In this group, 41.9% (67/160) once used SSZ but withdrew for adverse events and other reasons, while 17. 5% (28/160) withdrew for adverse events, of which the most common were gastrointestinal (8. 8%), skin (3. 8%) and liver toxicity (3. 1% ). Conclusion;Sulphaszlazine is not a common choice in the RA therapeutics in China, and the average dose of SSZ is lower than the standard dose of 2 to 3 g/d . The adverse events of SSZ are common; however, there are few severe adverse events or threat to life,SSZ is relatively safe in clinical practice.

关键词

柳氮磺吡啶/关节炎,类风湿/横断面研究

Key words

Sulphasalazine/ Arthritis, rheumatoid/ cross-sectional studies

分类

医药卫生

引用本文复制引用

刘田,王彩虹,王永福,杨荣,王国春,卢昕,朱平,陈丽娜,靳洪涛,刘湘源,孙琳,王秀茹,陈海英,崔刘福,舒荣,刘白鹭,张卓莉,李光韬,李振彬,杨静,李俊芳,贾彬,安媛,张风肖,陶杰梅,韩淑玲,林金盈,韦美秋,刘晓敏,柯丹,胡绍先,叶丛,杨岫岩,周云杉,李昊,黄慈波,高明,赖蓓,李兴福,宋立军,王轶,王晓元,穆荣,苏茵,张晓盈,栗占国,段天骄,朱佳鑫,李晓峰,王莉枝..柳氮磺吡啶在我国类风湿关节炎患者的用药现况调查[J].北京大学学报（医学版）,2012,44(2):188-194,7.

基金项目

国家"十一五"科技支撑计划项目(2008BAI59B01)资助（2008BAI59B01）

北京大学学报（医学版）

OA北大核心CSCDCSTPCD

ISSN：1671-167X

访问量0

下载量0

段落导航